4D Molecular Therapeutics, Inc. (FDMT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
5858 Horton Street
EmeryVille, CA 94608
United States of America (the)
Phone
510 505 2680
Sector
Healthcare
Industry
Biotechnology
Employees
227
First IPO Date
December 11, 2020
| Name | Title | Pay | Year Born |
| David H. Kirn | Co-Founder, President, CEO & Director | 1.23M | 1963 |
| Kristian Humer | CFO and Principal Financial & Accounting Officer | 116,247 | 1976 |
| John F. Milligan | Executive Chairman | 150,000 | 1961 |
| Noriyuki Kasahara | Chief Scientific Advisor & Member of Scientific Advisory Board | 201,288 | 1963 |
| Theresa Janke | Co-Founder & Chief of Staff | 652,315 | 1975 |
| Fariborz Kamal | Chief Technical Advisor | 892,868 | 1963 |
| An Song | Chief Translational Medicine Advisor | 0 | N/A |
| Scott Bizily | Chief Legal Officer & Corporate Secretary | 0 | 1972 |
| Julian Pei | Head of Investor Relations & Corporate Finance | 0 | N/A |
| Katy Barglow | Chief Technical Officer | 0 | N/A |
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.